Abstracts accepted for the 2011 ASCO Annual Meeting

28/04/2011

Twelve EORTC abstracts have been accepted for presentation at the 2011 ASCO Annual meeting to be held 3-7 June in Chicago, Illinois. A listing of these abstracts is given below.

Oral Presentations

EORTC Radiation Oncology Group

Abstract ID: 7004
Evaluation of disease-free survival as surrogate endpoint for overall survival using two individual patient data meta-analyses of adjuvant chemotherapy in operable non-small cell lung cancer. S. Michiels, A. Mauguen, D. Fisher, S. Burdett, R. Paulus, S.J. Mandrekar, C.P. Belani, F.A. Shepherd, T. Eisen, H. Pang, L. Collette, C. Le Pechoux, J.P. Pignon.

EORTC Radiation Oncology Group

Abstract ID: 3506
An analysis of preoperative chemoradiotherapy with 5FU/leucovorin for T3-4 rectal cancer on survival in a pooled analysis of EORTC 22921 and FFCD 9203 trials: Surrogacy in question? F. Bonnetain, J.F. Bosset, J.P. Gerard, G. Calais, T. Conroy, L. Mineur, O. Bouche, P. Maingon, O. Chapet, L. Radosevic-Jelic, N. Methy, L. Collette.

EORTC Melanoma Group

Abstract ID: 8506b
EORTC 18991 phase III trial: Long-term adjuvant pegylated interferon-α2b (PEG-IFN) versus observation in resected stage III melanoma: Long-term results at 7.6-years follow-up. A.M. Eggermont, S. Suciu, M. Santinami, W. Kruit, A. Testori, J. Marsden, C.J.A. Punt, M.E. Gore, R. MacKie, R. Dummer, D. Schadendorf, P. Patel, A. Spatz, U. Keilholz.

EORTC Genito-Urinary Cancers Group

Abstract ID: 4509
A randomized phase III study comparing paclitaxel-BEP (T-BEP) to standard BEP in patients with in intermediate prognosis germ cell cancer (GCC): An intergroup study of EORTC, German TCSG/AUO, MRC, and Spanish GCC group (EORTC 30983). R. De Wit, I.A. Skoneczna, K. Gedske Daugaard, M. de Santis, A. Garin, N. Aass, J.A. Witjes, P. Albers, J. White, J.R. Germa-Lluch, S. Osanto, S. Marreaud, L. Collette.

EORTC Genito-Urinary Cancers Group

Abstract ID: 4505
Final results from an EORTC (GU Group)/NCRI randomized phase III trial of adjuvant interleukin-2, interferon alpha, and 5-fluorouracil in patients with a high risk of relapse after nephrectomy for renal cell carcinoma (RCC). M. Aitchison, C.A. Bray, H. Van Poppel, R. Sylvester, J. Graham, C. Innes, L. McMahon, P.A. Vasey.

EORTC Soft Tissue and Bone Sarcoma Group

Abstract ID: LBA10002
PALETTE: A randomized, double-blind phase III trial of pazopanib versus placebo in patients with soft-tissue sarcoma (STS) whose disease has progressed during or following prior chemotherapy. An EORTC STBSG Global Network Study (EORTC 62072). W.T.A. Van Der Graaf, J.Y. Blay, S.P. Chawla, D.W. Kim, B. Bui Nguyen, P.G. Casali, P. Schöffski, M. Aglietta, A.P. Staddon, Y. Beppu, A. Le Cesne, H. Gelderblom, I.R. Judson, N. Araki, M. Ouali, S. Marreaud, R. Hodge, M. Dewji, A.P. Dei Tos, P. Hohenberger

Poster Sessions

EORTC Soft Tissue and Bone Sarcoma Group

Abstract ID: 10090
Exploratory analysis of prognostic factors for patients (pts) with advanced soft tissue sarcoma (ASTS) receiving combination chemotherapy: A joined study of the EORTC Soft Tissue and Bone Sarcoma Group and the French Sarcoma Group. N. Penel, M.M. Van Glabbeke, B. Bui Nguyen, M. Ouali, S. Mathoulin-Pelissier, S. Marreaud, A. Italiano, V. Brouste, P.C.W. Hogendoorn, J.M. Coindre, J.Y. Blay, P. Hohenberger.

EORTC Melanoma Group

Abstract ID: 8535
Active immunization towards the MAGE-A3 antigen in patients with metastatic melanoma: Four-year follow-up results from a randomized phase II study (EORTC16032-18031). W. Kruit, S. Suciu, B. Dreno, V. Chiarion-Sileni, L. Mortier, C. Robert, M. Maio, F. Lehmann, V.G. Brichard, A. Spatz, A.M. Eggermont, U. Keilholz.

EORTC Radiation Oncology Group and EORTC Head and Neck Cancer Group

Abstract ID: TPS197
EORTC 22071-24071: randomized, phase III trial of EGFR-antibody combined with adjuvant chemoradiation for patients with head and neck squamous cell carcinoma (HNSCC) at high risk of recurrence. C. Liberatoscioli, J. Langendijk, C. van Herpen, L. Collette, M. Oszahin, R. Karra, D. Lacombe, A. Gulyban, N. Gosselin, W. Budach.

EORTC Head and Neck Cancer Group

Abstract ID: 81245
Long-term results from EORTC24971/TAX323: Comparing TPF to PF in patients with unresectable squamous cell carcinoma of the head and neck (SCCHN). J.B. Vermorken, E. Remenar, C. Van Herpen, M. Degardin, J.S. Stewart, R. Karra Gurunath, C. Fortpied.

Poster Discussion Sessions

EORTC Melanoma Group

Abstract ID: 8523
The impact of gender on the outcome of malignant melanoma: Overview of seven EORTC phase III trials. A. Joosse, S. Collette, S. Suciu, E. de Vries, T. Nijsten, P. Patel, U.R. Kleeberg, U. Keilholz.

EORTC Lung Cancer Group

Abstract ID: 7025
Does disease control rate (DCR) at 9 and 18 weeks predict overall survival (OS) in patients with malignant pleural mesothelioma (MPM)? An individual patient data combined meta-analysis of 10 European Organisation for Research and Treatment of Cancer (EORTC) Lung Cancer Group (LCG) studies. L. Greillier, B. Hasan, P. Baas, J. Welch, J. Van Meerbeeck, R. Gaafar, R. Sylvester, D. Lacombe, M. O’Brien.

 Jennifer Crespo and Stéphanie Vandergooten

Facebooktwitterlinkedinmail

Find us

Avenue Emmanuel Mounier, 83/11
Brussels 1200
Belgium

Contact us

Follow us

Funding